The convertible note offering provides $243M in net cash to fund operations and pipeline development, reducing near-term financing risk. However, potential dilution of up to ~13.6M shares (roughly 8-10% of current shares outstanding based on $1.6B market cap) creates overhang. Monitor the stock price relative to the $24.76 conversion price, if SNDX trades above that level, conversion risk increases. The 2.25% coupon is low-cost debt for a biotech, but the 35% premium suggests management sees upside. Watch for the closing on June 10 and any subsequent use-of-proceeds announcements.
SNDX drugs
SNDX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 4 $18.02entry
- T+1 · 6mo ago −3.77%α −1.18% · $17.34
- T+5 · 5mo ago −0.61%α +1.94% · $17.91
- T+20 · 4mo ago +21.09%α +22.46% · $21.82
- T+60 · 3mo ago +8.44%α +6.55% · $19.54
Price Chart
How similar events traded
Executive Summary
Syndax Pharmaceuticals entered into subscription agreements to issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a private placement, expected to close on June 10, 2026. Net proceeds of approximately $243 million will be used for general corporate purposes including R&D, commercialization, and business development. The notes carry a 35% conversion premium over the June 3 closing price and are senior unsecured obligations maturing in 2031.
Key Financial Metrics
Key Facts
- $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031
- Net proceeds estimated at approximately $243 million
- Initial conversion price of approximately $24.76 per share, a 35% premium over the last reported sale price on June 3, 2026
- Notes mature June 15, 2031, interest payable semi-annually at 2.25%
- Company may not redeem notes prior to June 20, 2029
- Maximum of 13,631,400 shares of common stock issuable upon conversion based on initial maximum conversion rate
- Sale expected to close June 10, 2026, subject to customary closing conditions
- J. Wood Capital Advisors LLC acting as sole placement agent
Financial Impact
$250M principal raised, ~$243M net proceeds after fees and expenses
Risk Factors
- Potential dilution of up to 13.6M shares upon conversion, representing meaningful overhang
- Interest expense of ~$5.6M annually adds fixed cost to a commercial-stage biotech still scaling revenue
- If stock price declines, notes could still be converted under alternative conditions (trading price <98% of parity), accelerating dilution
- Proceeds used for general corporate purposes provides limited visibility on capital allocation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-256458 |
| Document: d65010d8k.htm | 0001193125-26-256458 |
| Document: d65010dex991.htm | 0001193125-26-256458 |
| Document: 0001193125-26-256458-index-headers.html | 0001193125-26-256458 |
| Document: 0001193125-26-256458-index.html | 0001193125-26-256458 |
| Document: 0001193125-26-256458.txt | 0001193125-26-256458 |
Track record
16 reports on SNDX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $9.45 Now $9.13 −3.39% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 2/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 2/10 No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $14.29 Now $9.13 −36.11% settles Feb 1
- Oct 29, 202618d ago 144 Neutral 2/10 Entry $13.65 Now $9.13 −33.11% settles Jan 28
- Jul 14, 202617w ago 8-K Bullish 7/10 Entry $24.13 to $17.03 Now $9.13 −62.16% ▼ −29.42% −32.80% vs SPY
- Jul 1, 202619w ago Press Release Neutral 2/10 Entry $21.82 to $18.20 Now $9.13 −58.16% ▼ −16.59% −20.16% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $17.91 to $20.56 Now $9.13 −49.02% ▲ +14.80% +10.40% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers